Cancer Research Targets  Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 68, 9643, December 1, 2008. doi: 10.1158/0008-5472.CAN-08-1539
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Renner, O.
Right arrow Articles by Carnero, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Renner, O.
Right arrow Articles by Carnero, A.

Cell, Tumor, and Stem Cell Biology

Activation of Phosphatidylinositol 3-Kinase by Membrane Localization of p110{alpha} Predisposes Mammary Glands to Neoplastic Transformation

Oliver Renner1, Carmen Blanco-Aparicio1, Maja Grassow1, Marta Cañamero2, Juan F.M. Leal1 and Amancio Carnero1

1 Experimental Therapeutics Program and 2 Biotechnology Program, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain

Requests for reprints: Amancio Carnero, Centro Nacional de Investigaciones Oncologicas, Melchor Fernandez Almagro 3, Madrid, 28029 Spain. Phone: 34-9173-28021; Fax: 34-9173-28051; E-mail: acarnero{at}cnio.es.

Key Words: PI3K • Akt • tumorigenesis • mouse model • mammary gland

Phosphatidylinositol 3-kinases (PI3K) constitute important regulators of various signaling pathways with relevance in cancer. Enhanced activation of p110{alpha}, the catalytic subunit of PI3K, was found in a high proportion of many human tumor types. We generated a mouse model in which PI3K is activated by forced recruitment of p110{alpha} to the membrane. Different transgenic lines expressing myristoylated p110{alpha} protein under the control of the epithelial-specific mouse mammary tumor virus promoter were selected according to different levels of PI3K activity and characterized. Delayed mammary gland involution and morphologic changes of the mammary ducts could be detected in young transgenic female mice. These changes were more pronounced in old animals, especially in mutiparous females, in which we observed increased ductal branching, alveolar hyperplasia, and intraductal neoplasia. We also observed a small percentage of mammary tumors. Crosses of myrp110{alpha} transgenic mice with heterozygous p53(+/–) knockout mice resulted in neither enhanced tumorigenesis nor in a stronger mammary gland phenotype. However, the CDK4 activating mutation (R24C) lead to increased tumorigenesis in transgenic myrp110{alpha} mice, emphasizing the postulated perturbation of the interaction of the CDK4/Rb/E2F cascade and the PI3K signaling in many human cancers. Interestingly, in tumors of myrp110{alpha} transgenic mice, we observed an increased phosphorylation of the estrogen receptor-{alpha}, a typical feature of human breast cancer. The model presented here will help to discover additional factors which influence the progression of preneoplastic lesions to tumors in the mammary gland and to explore antitumor therapies based on PI3K or estrogen receptor-{alpha} pathway inhibition. [Cancer Res 2008;68(23):9643–53]







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.